Rosebank, South Africa

Liugi Renzo Nassimbeni

This inventor holds 1 USPTO granted patent. Top assignee: Farmarc Nederland Bv. Active years: 2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Liugi Renzo Nassimbeni. Retrieved from https://idiyas.com/inventor/liugi-renzo-nassimbeni

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Liugi Renzo Nassimbeni: Innovator in Optical Resolution

Introduction

Liugi Renzo Nassimbeni is a notable inventor based in Rosebank, South Africa. He has made significant contributions to the field of chemistry, particularly in the area of optical resolution.

Latest Patents

Nassimbeni holds a patent for a "Process for the optical resolution of 3-(p-chlorophenyl)-glutaramide." This innovation showcases his expertise in developing methods that enhance the purity and effectiveness of chemical compounds.

Career Highlights

He is currently associated with Farmarc Nederland Bv, where he applies his knowledge and skills to advance pharmaceutical research and development. His work has been instrumental in creating solutions that benefit the industry.

Collaborations

Nassimbeni has collaborated with esteemed colleagues, including Alexander Franciscus Wildervanck and Mino Rodolfo Caira. These partnerships have fostered a creative environment that encourages innovation and progress.

Conclusion

Liugi Renzo Nassimbeni is a distinguished inventor whose work in optical resolution has made a lasting impact in the field of chemistry. His contributions continue to inspire future innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…